The Food and Drug Administration (FDA) is scheduled to host a public conference on Thursday, November 19th, 2020, to highlight how the use and effect of the cannabinoids may differ based on sex and gender.
The conference comes even as the federal government continues to develop regulations around CBD.
According to an agency description, the conference includes a presentation by the FDA’s Office of Women’s Health focusing on sex differences and the effects of CBD and other cannabinoids in pregnancy.
The agency revealed that the multidisciplinary scientific conference will significantly benefit researchers, educators, clinicians, and patients.
The conference will be streamed live through Adobe Connect, with participants expected to register in advance for free access.
Organizers of the event confirmed it would be held on Thursday from 9 am to 4 pm ET.
A federal register of the event was issued in September, indicating the registration deadline was Monday, November 16th, 2020. However, the system was still accepting new sign-ups as of Tuesday morning.
In the upcoming conference, speakers include various academic researchers and other health professionals, such as professors in the research department at the University of Colorado at Boulder and John Hopkins Hospital University, among others.
Panelists from FDA will represent the government’s side.
In the September outline of the event’s program, the FDA said that each panel discussion would include a Q&A session to respond to questions from attendees.
On the conference agenda, the FDA said that sex and gender are important factors to consider in CBD regulations because the compound could have varying physical effects for various people, especially in pregnant women.
A description of the Agency’s upcoming gender and sex conference says FDA recognizes the significant interest in cannabis and cannabis-derived components, particularly in CBD.
The agency’s Thursday public event intends to provide insights into the scientific evidence suggesting the presence or absence of sex and gender differences in use and response to CBD and other cannabinoids.